May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
A Novel Topical Antiviral Agent, PCL–016 (Picolinic Acid), Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model
Author Affiliations & Notes
  • E.G. Romanowski
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Science Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • K.A. Yates
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Science Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • R.P. Kowalski
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Science Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • F.S. Mah
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Science Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Y.J. Gordon
    The Charles T. Campbell Laboratory, UPMC Eye Center, Ophthalmology and Visual Science Research Center, Eye and Ear Institute, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • Footnotes
    Commercial Relationships  E.G. Romanowski, Novactyl, Inc. F, C; K.A. Yates, Novactyl, Inc. F; R.P. Kowalski, Novactyl, Inc. F, C; F.S. Mah, Novactyl, Inc. F, C; Y.J. Gordon, Novactyl, Inc. F, C.
  • Footnotes
    Support  Novactyl, Inc., NIH Grant EY08227, NIH Core Grant EY08098
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1024. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E.G. Romanowski, K.A. Yates, R.P. Kowalski, F.S. Mah, Y.J. Gordon; A Novel Topical Antiviral Agent, PCL–016 (Picolinic Acid), Inhibits Adenovirus Replication in the Ad5/NZW Rabbit Ocular Model . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1024.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Abstract:
 

The need for an effective antiviral to treat adenovirus (Ad) ocular infections persists. The goal of the current study was to determine the antiviral efficacy of a novel topical antiviral agent, PCL–016 (PCL, Picolinic Acid) on acute Ad replication in the Ad5/NZW rabbit ocular model. PCL–016, a pyridine carboxylate, acts by binding with the zinc associated with Zinc Finger Proteins to alter their structure and inhibit function.

 

25 NZW rabbits were topically inoculated in both eyes, following corneal scarification, with 1.5 x 106 pfu/eye of Ad5. On day 1, the rabbits were divided into 6 topical treatment groups: I – 1.5% PCL pH 7.0 (n=4); II – 0.8% PCL pH 7.0 (n=4); III – 0.369% PCL pH 7.0 (n=4); IV – 0.369% PCL pH 4.0 (n=4); V – 0.5% Cidofovir (CDV) (n=4); VI – Control (saline) (n=5). PCL and Control rabbits were treated in both eyes 4 times daily for 7 days, while CDV rabbits were treated in both eyes twice daily for 7 days. All eyes were cultured for virus on days 0, 1, 3, 4, 5, 7, 9, 11, and 14.

 

 

 

* p < 0.001 compared to the Control. p = 0.001 compared to CDV.

 

Topical 1.5% PCL, 0.8% PCL, 0.369% PCL (pH7), 0.369% PCL (pH4) and 0.5% CDV were significantly more effective than the Control in reducing Ad Positive Cultures/Total (Days 1–14) and the Duration of Ad Shedding in the Ad5/NZW rabbit ocular model. Although not statistically significant, there appears to be a trend toward concentration–dependent efficacy of PCL on the Duration of Ad Shedding. There was no apparent ocular toxicity associated with PCL concentrations. Additional studies of PCL in the experimental Ad5/NZW ocular model are indicated.

 

 
Keywords: adenovirus • antiviral drugs • conjunctivitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×